Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure

Fig. 3

Mean change in haematocrit levels between the baseline and evaluation periods in the PPS. The mean haematocrit levels (in percentage) in subjects of the per-protocol set (PPS) in the PDA-10 and Eprex® arms at baseline and evaluation periods. The error bars represent the standard deviation (SD)

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us